These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization. Van Lancker L, Petrarca R, Moutsouris K, Masaoutis P, Kampougeris G. Eur J Ophthalmol; 2017 May 11; 27(3):342-345. PubMed ID: 27739561 [Abstract] [Full Text] [Related]
7. Choroidal Neovascularization and Geographic Atrophy are Potential Complications of Early Onset Large Colloid Drusen. Carnevali A, Querques G. Ophthalmic Surg Lasers Imaging Retina; 2017 Jul 01; 48(7):586-590. PubMed ID: 28728186 [Abstract] [Full Text] [Related]
8. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography. Abri Aghdam K, Seidensticker F, Pielen A, Framme C, Junker B. Lasers Surg Med; 2016 Sep 01; 48(7):668-77. PubMed ID: 27111455 [Abstract] [Full Text] [Related]
9. Intravitreal bevacizumab for extrafoveal choroidal neovascularization after ocular trauma. De Benedetto U, Battaglia Parodi M, Knutsson KA, Librando A, Bandello F, Lanzetta P, Iacono P. J Ocul Pharmacol Ther; 2012 Oct 01; 28(5):550-2. PubMed ID: 22554238 [Abstract] [Full Text] [Related]
10. Rescue therapy with intravitreal aflibercept for choroidal neovascularization secondary to choroidal osteoma non-responder to intravitreal bevacizumab and ranibizumab. Saitta A, Nicolai M, Neri P, Reibaldi M, Giovannini A, Mariotti C. Int Ophthalmol; 2015 Jun 01; 35(3):441-4. PubMed ID: 25761547 [Abstract] [Full Text] [Related]